| Authors: |
Muñoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA.; Mayo Clinic, Pheonix, AZ, USA., Locke FL; Moffitt Cancer Center, Tampa, FL, USA., Reagan PM; University of Rochester School of Medicine, Rochester, NY, USA., Goy A; John Theurer Cancer Center, Hackensack, NJ, USA., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA, USA., Hill BT; Cleveland Clinic Foundation, Cleveland, OH, USA., Timmerman JM; UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Flinn IW; Tennessee Oncology & One Oncology, Nashville, TN, USA., Miklos DB; Stanford University, Stanford, CA, USA., Pagel JM; Swedish Cancer Institute, Seattle, WA, USA., Kersten MJ; Amsterdam UMC, University of Amsterdam Cancer Center, Amsterdam, Netherlands., Forcade E; Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Pessac, France., Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany., Houot R; CHU Rennes, Université Rennes, Inserm & EFS, Rennes, France., Beitinjaneh A; University of Miami, Miami, FL, USA., Zheng D; Kite, a Gilead Company, Santa Monica, CA, USA., Chang M; Kite, a Gilead Company, Santa Monica, CA, USA., Zhang W; Kite, a Gilead Company, Santa Monica, CA, USA., Shen RR; Kite, a Gilead Company, Santa Monica, CA, USA., Khalid RD; Kite, a Gilead Company, Santa Monica, CA, USA., Kloos I; Kite, a Gilead Company, Santa Monica, CA, USA., Wang ML; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org. |
